alexa Jalal naghinezhad | OMICS International

Journal of Cellular and Molecular Pharmacology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Jalal naghinezhad

Molecular Pathology Cancer Research Center, Iran

PI3K/AKT/mTOR Pathway in ATLL: from Basic Biology to Preclinical Study

Adult T-cell leukemia/ lymphoma (ATLL) is high resistance fatal malignancy which has a poor prognosis and exhibits resistance to conventional chemotherapy. The development of novel therapies for ATLL relies on a comprehensive understanding of the occurrences that result in cellular survival and proliferation regulating pathways that control growth ... Read More»

Jalal naghinezhad

: J Cell Mol Pharmacol 2019, 3: 104


Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article